Bio Balance offers a unique opportunity to partner
into a ground-breaking process to create and
develop better drugs. Bio Balance is committed
to offering the best value to pharmaceutical
or biotech partners for new drug development.
Bio Balance currently has an improved dobutamine
for heart failure and isoproterenol for emergency
management (DOB+ and ISO+). Bio Balance is seeking
a collaborative partner to take these potential
products to the next level of development. Other
areas of potential development include enhancing
drugs that treat Parkinson's disease, memory
loss, asthma, heart failure, or other diseases
that require new or improved drugs.
Therapeutic
Compositions to Prevent Desensitization
Specific compositions from the patent titled
"Compositions to enhance the efficacy and
safety of bio-pharmaceutical drugs" (US
6,593,094; July 15, 2003) are available for
licensing to either biotechnology or pharmaceutical
firms.
Our
technology is at the forefront of cutting edge
science, but just beginning. Although agonist/antagonist
combinations have been used before, we have
perfected the science so that we have the best
method of determining the optimal agonist/antagonist
ratio. This means better and safer drugs. Almost
one third of all drugs could be improved by
this technology. This technology is available
for licensing or collaborative development.
One
of the perils of drug development is the occurrence
of desensitization, which is also called tolerance,
fade, tachyphylaxis or down-regulation. Many
in the industry believe that by selecting the
proper dosage regime drug-receptor desensitization
can be minimized or prevented. Rightly or wrongly,
they create a tightrope that patients and doctors
must walk when utilizing these types of medications.
This may affect anywhere from 30 to 50 percent
of all pharmaceuticals and be a fertile area
for drug development and improvement in the
future. Given some of the disturbing reports
that shown upwards of 90,000 cases per year
of reported medical errors, the production of
safer drugs should be a top priority in the
pharmaceutical field. Yet why haven't the major
companies done more to produce safer drugs?
A partial explanation would be that it is much
more expensive to ensure safer drugs, but an
alternative explanation may be that they lack
the technology to understand and correct the
problem. Certainly, the major companies would
want the safest product on the market. This
would not only make sense from a medical standpoint,
but a marketing one as well. Safer drugs require
that all of the variables of drug development
be evaluated and adjusted for the greatest number
of people using these medications. Surprisingly,
the safest drugs may come from using agonist/antagonist
combinations in ways to prevent, diminish or
control drug-receptor desensitization. This
would be analogous to creating designer partial
agonists in ways that have been previously overlooked,
but would offer a new technology for enhancing
the safety and efficacy of many pharmaceuticals.
The following list suggests some of the advantages
of agonist/antagonist compositions:
| Less
expensive to develop. |
| Better
control of the therapeutic response. |
| They
could enhance existing pharmaceuticals. |
| Increase
the patent life of many drugs. |
| These
compositions can be licensed for applications
in specific fields (eg. cardiovascular,
pulmonary, renal, etc.). |
| Potentially
quick acceptance by physicians as a technically
superior design of previously accepted drugs |
| Much
of the toxicity, carcinogenicity and teratogenic
testing has been done. |
| Trials
could be started rapidly. |
| Molecules
do not need to be designed from scratch.
|
| Could
salvage previously discarded molecules due
to excessive desensitization or fade at
the receptor. |
| Could
be used to determine the optimal mixtures
of chiral molecules |
| |
|
Contact
Bio Balance about Licensing opportunities
-
Dr. Richard Lanzara
e-mail: rlanzara@bio-balance.com
|
.
